What is the price target for ARWR stock?
19 analysts have analysed ARWR and the average price target is 81.18 USD. This implies a price increase of 16.78% is expected in the next year compared to the current price of 69.51.
ARROWHEAD PHARMACEUTICALS IN (ARWR) Forecast, Price Target & Analyst Ratings
NASDAQ:ARWR • US04280A1007
Current stock price
69.51 USD
+1.53 (+2.25%)
At close:
69.5 USD
-0.01 (-0.01%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARROWHEAD PHARMACEUTICALS IN (ARWR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q2 / 2026
- EPS Estimate
- -$1.21
- Revenue Estimate
- 77.204M
Price Target Details & History
Consensus Price Target and Range
Mean target
$81.17
Upside
+ 16.78%
From current price of $69.51 to mean target of $81.17, Based on 19 analyst forecasts
Low
$35.35
Median
$81.60
High
$115.50
Price Target Revisions
1 Month
-0.31%
3 Months
4.61%
Price Target Summary
19 Wall Street analysts provided a forecast for the next 12 months for ARWR. The average price target is 81.18 USD. This implies a price increase of 16.78% is expected in the next year compared to the current price of 69.51.
The average price target has been revised upward by 4.61% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
ARWR was analyzed by 19 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about ARWR.
In the previous month the buy percentage consensus was at a similar level.
ARWR was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-22 | B. Riley Securities | Maintains | Buy -> Buy |
| 2026-01-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-01-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-01-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-01-07 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-01 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-19 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q2 / 2026
- EPS Estimate
- -$1.21
- Revenue Estimate
- 77.204M
- Revenue Q2Q
- -85.78%
- EPS Q2Q
- -144.04%
- Number of Analysts
- 14
Next Earnings Revisions
Revenue (1 Month)
-1.15%
Revenue (3 Months)
10.14%
EPS (1 Month)
-0.62%
EPS (3 Months)
-6.58%
Next Earnings Summary
ARWR is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -1.21 USD and the consensus revenue estimate is 77.20M USD.
The next earnings revenue estimate has been revised upward by 10.14% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 240.7M -1.03% | 3.551M -98.52% | 829.448M 23,258.15% | 460.2M -44.52% | 327.83M -28.76% | 552.63M 68.57% | 884.75M 60.10% | 1.539B 73.95% | 2.094B 36.06% | 3.19B 52.34% | 4.036B 26.52% | |
| EBITDA YoY % growth | -192.5M -14.52% | -582.485M -202.59% | 122.274M 120.99% | -321.061M -362.58% | -446.405M -39.04% | -500.429M -12.10% | -135.864M 72.85% | 565.08M 515.92% | 1.087B 92.36% | N/A | N/A | |
| EBIT YoY % growth | -205M -14.85% | -601.08M -193.21% | 98.346M 116.36% | -453.626M -561.25% | -596.233M -31.44% | -424.557M 28.79% | -243.29M 42.70% | 358.86M 247.50% | 782.97M 118.18% | 1.412B 80.34% | 2.044B 44.76% | |
| Operating Margin | -85.17% | -16,927.06% | 11.86% | -98.57% | -181.87% | -76.82% | -27.50% | 23.32% | 37.39% | 44.26% | 50.64% | |
| EPS YoY % growth | -1.92 -14.29% | -5.01 -160.94% | -0.08 98.40% | -3.53 -4,307.25% | -4.28 -21.40% | -3.03 29.19% | -2.27 24.95% | 2.47 208.67% | 5.39 118.16% | 10.13 87.92% | 15.21 50.08% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.21 -144.04% | -1.43 -13.11% | -1.26 -599.27% | -1.39 -730.55% | -1.49 -22.97% | -1.52 -6.40% | -1.23 1.94% |
| Revenue Q2Q % growth | 77.204M -85.78% | 38.193M 37.55% | 38.97M -84.81% | 43.452M -83.54% | 31.79M -58.82% | 34.544M -9.55% | 161.19M 313.63% |
| EBITDA Q2Q % growth | -177.133M -145.13% | -187.002M -26.35% | -150.858M -321.74% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -180.92M -147.46% | -196.204M -18.52% | -154.293M -449.82% | -208.884M -611.86% | -215.617M -19.18% | -220.661M -12.46% | -164.824M -6.83% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-235.86%
EPS Next 5 Year
101.11%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-10.77%
Revenue Next 5 Year
14.62%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-105.85%
EBIT Next 5 Year
49.99%
ARROWHEAD PHARMACEUTICALS IN / ARWR Forecast FAQ
When does ARROWHEAD PHARMACEUTICALS IN (ARWR) report earnings?
ARROWHEAD PHARMACEUTICALS IN (ARWR) will report earnings on 2026-05-07.
What are the consensus estimates for ARROWHEAD PHARMACEUTICALS IN (ARWR) next earnings?
The consensus EPS estimate for the next earnings of ARROWHEAD PHARMACEUTICALS IN (ARWR) is -1.21 USD and the consensus revenue estimate is 77.20M USD.
What is the number of analysts for ARWR stock?
The number of analysts covering ARROWHEAD PHARMACEUTICALS IN (ARWR) is 19.